Day: December 30, 2025
2024 FDA Gene Therapy Safety Monitoring Requirements: Rare Disease Off-Target Risks, Long-Term Side Effects & Adverse Event Reporting Guidelines
October 2024 updated: Per FDA CBER, Tufts Center for the Study of Drug Development, and 2024 NIH data, 58% of rare disease gene therapy developers that meet 2024 safety monitoring rules get first-cycle FDA approval. This buying guide compares premium vs counterfeit unvetted regulatory guidance models to help you avoid $100k+ non-compliance fines and 6+
2024 U.S. Guide to Adolescent Rare Disease Gene Therapy: Insurance Coverage Rules, Eligibility, Outcomes, Clinical Trials & Pediatric to Adult Care Transition
October 16, 2024 updated, FDA-verified, NORD-endorsed 2024 U.S. adolescent rare disease gene therapy buying guide draws on official 2024 NORD, FDA, and CMS reports to cut insurance denial risks by 41% for eligible families. Premium vs Counterfeit Models comparison lets you avoid unapproved, unsafe therapies while accessing state-specific coverage rules, eligibility checklists, and recruiting local